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The etiology of biliary tract cancer is obscure, but there are
evidences that bile acid plays a role in carcinogenesis. To find
the association between biliary tract cancer and bile acid, this
study compared the bile acid concentration and composition
among patients with biliary cancer, biliary tract stones, and no
biliary disease. Bile was compared among patients with biliary
tract cancer (n = 26), biliary tract stones (n = 29), and disease
free controls (n = 9). Samples were obtained by percutaneous
transhepatic biliary drainage, endoscopic nasobiliary drainage,
or gallbladder puncture, and analyzed for cholic, deoxycholic,
chenodeoxycholic, lithocholic, and ursodeoxycholic acid com-
position. Total bile acid concentration was lower in the cancer
group than the biliary stone and control groups; the propor-
tions of deoxycholic (2.2% vs. 10.2% and 23.6%, p < 0.001
and p < 0.001, respectively) and lithocholic acid (0.3% vs.
0.6% and 1.0%, p = 0.065 and p < 0.001, respectively) were
also lower. This result was similar when disease site was
limited to bile duct or gallbladder. Analysis of cases with
bilirubin 2.0 mg/dL also showed lower total bile acid
concentration and deoxycholic acid composition in the cancer
group compared to controls (5.7% vs. 23.6%, p = 0.003).
Although the presence of bile duct obstruction explains some
of the difference in total concentration and composition of
bile acid, there are other contributing mechanisms. We suspect
the alteration of bile acid transport might decrease bile acid
excretion and cause the accumulation of carcinogenic bile acid
in bile duct epithelium.
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INTRODUCTION
Bile duct cancer originates from the bile duct
epithelium; it is divided into intrahepatic cholan-
giocarcinoma, extrahepatic bile duct cancer, and
gallbladder cancer. Known risk factors include
bile stasis, chronic inflammation, chronic hepatitis,
carcinogenic exposures, choledochal cyst, liver
fluke (especially in Asia), and, in Western coun-
tries, primary sclerosing cholangitis. However, in
most cases, a risk factor is hard to find.
1
Bile acid is a common denominator in all risk
factors. Bile is composed of primary bile acids,
such as cholic and chenodeocycholic acid, derived
directly from cholesterol, secondary bile acids
such as deoxycholic and lithocholic acid, and
tertiary bile acids such as ursodeoxycholic acid.
Physiologically, these acids are complexed with
taurine or glycine.
1 Hydrophobic acids such as
deoxycholic acid are known to be associated with
carcinogenesis. In contrast, hydrophilic acids such
as ursodeoxycholic acid have protective effects
such as prevention of gallstones through desatura-
tion of bile and reduction of cellular changes seen
in hepatic and biliary diseases.
2-6 In animal
models, cholic and deoxycholic acid have been
implicated in the development of bile duct can-
cer.
7,8 Increased levels of deoxycholic and lithocholic
acid concentrations have also been reported in
patients with choledochal cyst and anomalous
union of the pancreaticobiliary duct.
9 Although
studies have shown that bile acid can be carcino-
genic, there are few reports evaluating bile acid
composition in biliary tract cancer, likely due to
the rarity of this disease. Therefore, the role of bile
acid in the development of biliary tract cancer
remains elusive.
In this study, bile concentration and composi-
tion were compared among subjects with biliary
tract cancer, biliary tract stones, and controls. In
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addition, subjects with gallbladder diseases and
bile duct diseases were compared among them
separately. Based on the difference of bile compo-
sition in patients with biliary cancer, biliary stone,
and no biliary disease, we sought to elucidate the
role of bile acid in the development of biliary tract
cancer.
MATERIALS AND METHODS
Patients
Between April 2003 and October 2004, patients
with biliary tract cancer, diagnosed by tumor
markers, endoscopic retrograde cholangiopancrea-
tography (ERCP), computerized tomography (CT),
or magnetic resonance image (MRI), and confir-
med by clinical course, cytology, and tissue biopsy,
were enrolled. Twenty-six patients with confirmed
diagnosis who gave informed consent were
consecutively enrolled.
For comparison, a biliary stone group, com-
posed of patients with cholelithiasis, choledocho-
lithiasis, or intrahepatic stone, and a control
group, composed of liver transplant donors with
no biliary disease, were included. Patients with
chronic liver disease, including biliary cirrhosis,
small bowel diseases, or diabetes mellitus, were
excluded. All patients supplied informed consent,
and approval was granted by the Ethical Com-
mittee for Clinical Research of the Institutional
Review Board of Yonsei Medical Center, Korea.
Methods
Bile juice collection
Bile was collected post inflammation in cases
who underwent percutaneous transhepatic bile
drainage (PTBD) or endoscopic naso-biliary
drainage (ENBD). Post inflammation was defined
as the absence of fever and leukocytosis. However,
since it was unethical for bile juice collection to
interfere with the treatment, it was allowed to
collect bile juice from patients with leukocytosis if
they were under antibiotics treatment and did not
have fever. Surgical cases had bile (10 cc) collected
via gallbladder puncture. Samples were stored at
-70 immediately after collection until analysis.
Prior to collection, all patients had serum chem-
istries and complete blood cell counts.
Analysis of bile acid
Bile acids were separated by high pressure
liquid chromatography (HPLC), and analyzed
using the Nanospace SI-2 HPLC system (Shiseido
Co., Ltd, Tokyo, Japan) and Photodiodearray
detector (Thermo Electron Co., Ltd, Waltham,
MA, USA). Other HPLC conditions are summa-
rized in Table 1.
Among bile acids, cholic acid (CA), chenodeo-
xycholic acid (CDCA), deoxycholic acid (DCA),
lithocholic acid (LCA), and ursodeoxycholic acid
(UDCA) were analyzed. Standard reagents were
obtained from Sigma-Aldrich (St Louis, MO,
USA). Acetonitrile was combined with both trieth-
yamine and 2,4-dibromoacetophenone to make
TEA and derivatization reagent, respectively.
Standard solution of each acid was made by
heating a mixture of diluted, commercially pur-
chased acid with TEA and derivatization reagent
at 80 for 40 minutes; each solution was then
cooled at room temperature and filtered with a
0.45- m membrane filter. To evaluate bile com μ -
position, test solution was created. NaOH (4 N, 3
mL) was added to the bile sample (1 mL), hydro-
lyzed at 100 for 3 hours, cooled at room tem-
perature, then mixed with HCl (6 N, 3 mL) and
compounded with ether (6 mL). Dried supernatant
Table 1. HPLC Conditions for Bile Acid Determination
Column Capcellpak MG C18
(4.6 ×150 mm, 5 m) μ
Detector PDA (wavelength : 254 nM)
Flow rate 1.0 mL/min
Injection volume 10 L μ
Mobile phase Methanol 0.1% phosphoric acid
0 min 80% 20%
50 min 90% 10%
55 min 90% 10%
56 min 80% 20%
60 min 80% 20%
HPLC, High pressure liquid chromatography; PDA, Photo-
diodearray detector.Bile Acid in Biliary Tract Cancer
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(3 mL), was then dissolved in methanol (2 mL),
and eluate (1 mL) was mixed with TEA (1 mL)
and derivatization reagent (1 mL) and heated by
water bath at 80 for 40 minutes. It was then
cooled at room temperature and filtered with a
0.45 m membrane filter. The solution was an μ -
alyzed by HPLC, and each bile acid concentration
was measured. The proportion of each bile acid
relative to the sum of total bile acid was com-
puted.
Statistics
Results were presented as means (± standard
deviation) and ranges. Results of serum chem-
istries, total bile acid concentration, and com-
ponent bile acid proportions among each study
group were compared using the Mann-Whitney U
test. SPSS (Windows 11.0) was used for statistical
analysis; a p value less than 0.05 was considered
significant.
RESULTS
Demographic characteristics
Of 64 total patients, 26 had biliary tract cancer,
29 had biliary stone disease, and 9 were controls.
The male to female ratio was 34:30; average age
was 56 ± 16 years. Among the 26 patients with a
biliary tract cancer, 20 had bile duct cancer and 6
had gallbladder cancer; surgery, PTBD, and ENBD
was performed in 3 (11.5%), 18 (69.2%), and 5
(19.2%) cases, respectively. Fourteen out of 26
patients had cytological or histologic confirmation
of cancer diagnosis. Among the 29 patients with
biliary stones, surgery, PTBD, and ENBD was
performed in 17 (58.6%), 5 (17.2%), and 7 (24.1%),
respectively. All 9 controls underwent surgery
(Table 2).
Significant differences in liver function test were
found between both the biliary stone patients and
controls when compared to the cancer cases.
Bilirubin, alkaline phosphatase, aspartate trans-
aminase, and alanine aminotransferase levels were
significantly higher in the cancer group than in
patients with biliary stones and controls. Albumin
levels were lower in the cancer group compared
to controls. There were no differences in white
blood cell count or cholesterol levels among
subjects (Table 3).
Bile acid analysis
Comparison of bile acid concentration among
biliary tract cancer, biliary tract stone, and normal
control groups
Total concentration of bile acid and the pro-
portion of DCA in the biliary tract cancer, biliary
stone, and control groups were 1800.7 ppm, 4005.4
ppm, and 12569.1 ppm, and 2.2%, 10.2%, and
23.6%, respectively. The cancer group had both
significantly lower total bile concentration (p =
0.001, p < 0.001) and DCA proportion (p < 0.001, p
< 0.001). The proportion of LCA was also signi-
ficantly lower in the cancer group compared to
controls (0.3% vs. 1.0%, p < 0.001) (Table 4).
Comparison among gallbladder cancer, choleli-
thiasis, and control groups
Analysis was repeated limiting biliary tract
disease to the gallbladder site for the cancer and
stone groups. Both total bile acid concentration
and DCA proportion were found to be lower in
Table 2. Case Demographics
Category No. of patients
Age (yrs) 55.95 ± 16.78 (range: 16 - 92)
Sex (M : F) 34 : 30
Cancer (n = 26)
Bile duct cancer 20
Intrahepatic cancer 2
Perihilar cancer 12
Extrahepatic cancer 6
GB cancer 6
Stone (n = 29)
IHD stone 6
CBD stone 8
GB stone 15
Normal control* (n = 9) 9
*Healthy living donor.Table 4. Bile Acid Comparison among Biliary Tract Cancer, Stone, and Control Groups
Groups [Mean ± SD]
Cancer (n = 26) Stone (n = 29) Normal* (n = 9)
Bile acid (ppm) 1,800.7 ± 3,890.3 4,005.4 ± 3,836.5 12,569.1 ± 6268.4
Range 16.9 ~ 19439.9 47.9 ~ 14982.5 8210.1 ~ 28794.7
p value 0.001 < 0.001
Ursodeoxycholic acid (%) 15.6 ± 20.0 9.3 ± 2.9 2.7 ± 1.2
p value 0.209 0.271
Cholic acid (%) 43.0 ± 16.7 41.4 ± 18.2 33.8 ± 5.5
p value 0.601 0.059
Chenodeoxycholic acid (%) 39.2 ± 18.5 38.6 ± 10.1 39.0 ± 4.9
p value 0.698 0.546
Deoxycholic acid (%) 2.2 ± 8.1 10.2 ± 10.5 23.6 ± 6.4
p value < 0.001 < 0.001
Lithocholic acid (%) 0.3 ± 0.8 0.6 ± 1.1 1.0 ± 0.8
p value 0.065 < 0.001
*Healthy living donor.
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Table 3. Biochemical Characteristics
Biochemical parameters
Groups [Mean ± SD]
Cancer Stone Normal*
Cholesterol (mg/dL) (normal range: 100 ~ 220) 158 ± 80 157 ± 50 141 ± 42
p value 0.659 0.806
Bilirubin (mg/dL) (normal range: 0.2 ~ 1.2) 8.6 ± 8.9 2.3 ± 4.7 0.6 ± 0.4
p value < 0.001 < 0.001
Alkaline phosphatase (IU/L) (normal range: 38 ~ 115) 384 ± 323 174 ± 221 72 ± 20
p value < 0.001 < 0.001
Aspartate transaminase (IU/L) (normal range: 13 ~ 34) 77 ± 68 65 ± 110 17 ± 2
p value 0.010 < 0.001
Alanine aminotransferase (IU/L) (normal range: 5 ~ 46) 62 ± 55 48 ± 65 13 ± 5
p value 0.027 < 0.001
Albumin (g/dL) (normal range: 3.3 ~ 5.3) 3.3 ± 0.8 3.7 ± 0.7 4.6 ± 0.4
p value 0.058 < 0.001
White blood cell count (/ L) (normal range: 4000 μ ~ 10800) 7873 ± 4383 9842 ± 7729 6507 ± 1510
p value 0.879 0.288
Hemoglobin (g/dL) (normal range: 13.0 ~ 17.0) 11.3 ± 2.2 12.4 ± 1.5 14.1 ± 1.2
p value 0.033 0.001
*Healthy living donor.Bile Acid in Biliary Tract Cancer
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the cancer group compared to the stone and con-
trol groups; concentrations and proportions were
1346.3 ppm, 5125.5 ppm, and 12569.1 ppm (p =
0.073, p = 0.001), and 6.2%, 14.2%, and 23.6% (p =
0.047, p = 0.031) respectively. LCA was signifi-
cantly lower in the cancer group compared to
controls (0.2% vs. 1.0%, p = 0.016) (Table 5).
Comparison among bile duct cancer, choledocho-
lithiasis, and control groups
Results from analysis limiting biliary tract
diseases to the bile duct were 1936.9 ppm, 2805.3
ppm, and 12569.1 ppm for the total bile concen-
tration in the cancer, stone, and control groups,
respectively. The cancer group had significantly
lower total concentration (p = 0.006, p < 0.001). The
proportion of CA in the cancer group was signi-
ficantly higher than controls (45.0% vs. 33.8%, p =
0.021). DCA was lower in the cancer group
compared to the stone and control groups (1.0%
vs. 5.8% vs. 23.6%, p = 0.027, p < 0.001, respec-
tively). LCA was also significantly lower in the
cancer group than control group (0.3% vs. 1.0%,
p < 0.001) (Table 6).
Comparison among non-obstructive biliary
diseases
To exclude the effect of bile duct obstruction,
cases with bilirubin 2.0 mg/dL, without sup-
port of bile drainage procedures, were analyzed.
Analysis included 3 gallbladder cancer cases, 13
cholelithiasis cases, 7 bile duct cancer cases, 9
choledocholithiasis cases, and 9 controls. Between
the cancer and stone group, only alkaline phos-
phatase was different. Comparison between the
cancer and control groups was similar to the
results before exclusion. (data not shown) Total
bile acid concentration in the cancer, stone, and
control groups was 3298.6 ppm, 4522.8 ppm, and
12569.1 ppm, respectively. The cancer group had
significantly lower total concentration (p = 0.001),
higher CA proportion (50.9% vs. 33.8%, p = 0.009),
lower DCA proportion (5.7% vs. 23.6%, p = 0.003),
and lower LCA proportion (0.3% vs. 1.0%, p =
0.009) compared to the normal control group
(Table 7).
Table 5. Bile Acid Comparison among Gallbladder Cancer, Cholelithiasis, and Control Groups
Groups [Mean ± SD]
Gall bladder cancer (n = 6) Gall bladder stone (n = 15) Normal* (n = 9)
Bile acid (ppm) 1,346.3 ± 1,906.9 4,005.4 ± 3,836.5 12,569.1 ± 6268.4
Range 16.9 ~ 5,145.0 47.9 ~ 14,982.5 8,210.1 ~ 2,8794.7
p value 0.073 0.001
Ursodeoxycholic acid (%) 10.0 ± 9.8 5.0 ± 8.8 2.7 ± 1.2
p value 0.132 0.289
Cholic acid (%) 36.3 ± 25.0 39.2 ± 14.8 33.8 ± 5.5
p value 0.938 0.906
Chenodeoxycholic acid (%) 47.4 ± 30.0 41.1 ± 10.1 39.0 ± 4.9
p value 0.938 0.814
Deoxycholic acid (%) 6.2 ± 15.2 14.2 ± 11.0 23.6 ± 6.4
p value 0.047 0.031
Lithocholic acid (%) 0.2 ± 0.6 0.6 ± 1.3 1.0 ± 0.8
p value 0.430 0.016
*Healthy living donor.Table 7. Bile Acid Comparison among Non-obstructed Cancer, Stone, and Control Groups
Groups [Mean ± SD]
Cancer (n = 10) Stone (n = 22) Normal* (n = 9)
Bile acid (ppm) 3,298.6 ± 5,877.9 4,522.8 ± 4,048.8 12,569.1 ± 6,268.4
Range 224.7 ~ 19,439.9 47.9 ~ 14,982.5 8,210.1 ~ 28,794.7
p value 0.088 0.003
Ursodeoxycholic acid (%) 4.3 ± 6.2 10.7 ± 17.2 2.7 ± 1.2
p value 0.618 0.682
Cholic acid (%) 50.9 ± 12.5 39.7 ± 19.3 33.8 ± 5.5
p value 0.074 0.009
Chenodeoxycholic acid (%) 38.9 ± 9.0 37.9 ± 10.3 39.0 ± 4.9
p value 0.684 1.000
Deoxycholic acid (%) 5.7 ± 12.6 10.9 ± 10.8 23.6 ± 6.4
p value 0.082 0.003
Lithocholic acid (%) 0.3 ± 0.6 0.6 ± 1.2 1.0 ± 0.8
p value 0.314 0.009
*Healthy living donor.
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Table 6. Bile Acid Comparison among Bile Duct Cancer, Choledocholithiasis, and Control Groups
Groups [Mean ± SD]
Bile duct cancer (n = 20) Bile duct stone (n = 14) Normal* (n = 9)
Bile acid (ppm) 1,936.9 ± 4,344.2 2805.3 ± 2,167.7 12,569.1 ± 6,268.4
Range 52.3 ~ 19,439.9 245.0 ~ 7,823.0 8,210.1 ~ 28,794.7
p value 0.006 < 0.001
Ursodeoxycholic acid (%) 17.3 ± 22.1 13.9 ± 19.9 2.7 ± 1.2
p value 0.788 0.342
Cholic acid (%) 45.0 ± 13.6 43.9 ± 21.5 33.8 ± 5.5
p value 1.000 0.021
Chenodeoxycholic acid (%) 36.5 ± 13.7 35.9 ± 9.8 39.0 ± 4.9
p value 0.834 0.509
Deoxycholic acid (%) 1.0 ± 4.3 5.8 ± 8.2 23.6 ± 6.4
p value 0.027 < 0.001
Lithocholic acid (%) 0.3 ± 0.9 0.5 ± 0.9 1.0 ± 0.8
p value 0.171 < 0.001
*Healthy living donor.Bile Acid in Biliary Tract Cancer
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DISCUSSION
Bile is composed mostly of water along with
bile acid, bile pigment, cholesterol, minerals, and
fat. Bile acid is produced in hepatocytes via the
metabolism of cholesterol, and contributes to
formation of bile, excretion of cholesterol, and
absorption of fatty meals and lipophilic vitamins.
1
The most basic study to evaluate the role of
hydrophobic bile acid in biliary tract cancer
would be to measure each bile acid in the bile of
patients with biliary tract cancer. However, there
are few such studies. Strom et al. reported dif-
ferences in bile composition among subjects with
gallbladder cancer, cholelithiasis, and no disease,
but found no significant difference in the sus-
pected carcinogen, LCA.
10 Lee et al. reported
increased DCA in patients with bile duct cancer,
yet found no significant difference from biliary
stone patients.
11 These studies, however, explored
a limited spectrum of disease and had no proper
controls. Our study analyzed the total bile acid
concentration in biliary cancer, biliary stone, and
control groups, and also evaluated differences
based on disease sites (gallbladder and bile duct).
Since DCA is associated with gallstone formation,
bile from normal subjects was used as controls.
12
We found that the proportion of secondary bile
acids, the most strongly suspected carcinogens,
were low in bile from subjects with biliary tract
cancer. Theoretically, this is because primary bile
acid cannot reach bowel sites where conversion to
secondary bile acid occurs. However, there are
evidences that this may not be the sole reason.
Analysis which excluded duct obstruction cases
also showed lower DCA proportions in the cancer
group. Strom et al. found similar results of this
decrease in bile acids in cancer cases, even after
removal of clinical obstruction.
10 In addition, the
total bile acid concentration was lower in the
cancer group. Contrary to this result, it is known
that bile duct obstruction increases bile acid
synthesis.
13 In addition, the increase of bile acid in
serum caused by obstruction should have
increased bile acid level in bile.
14 Therefore,
obstruction alone can not explain the decrease of
total and secondary bile acid.
Besides obstruction, decreased excretion of bile
acids by bile duct epithelium might cause the
differences seen.
10 In vivo, both inflammation and
obstruction are known to alter expression of the
bile acid transporter.
15 In animal models, ligation
of the bile duct causes diminished expression of
the bile salt export pump and multidrug resis-
tance associated proteins, thereby diminishing bile
salt output.
16-18 Various endotoxin and inflam-
matory cytokines also decrease bile salt excre-
tion.
19 In addition, decreased bile acid is asso-
ciated with liver bile acid accumulation.
20 The
alteration of the bile acid transport pathway may
cause decreased excretion of bile acid, and
accumulation of toxic and even carcinogenic bile
acid in the bile duct epithelium.
As biliary epithelial cells constantly transport
strongly cytotoxic components of bile, a chemical
carcinogenesis in the bile duct system induced by
bile composition changes likely exists. There are
interesting reports that the secondary bile acid,
DCA, does not cause dysplasia through cytotoxic
process alone, but rather augments effects of
carcinogens.
3 For example, tauroursodeoxycholic
acid has been found to promote carcinogenesis of
intrahepatic bile duct cancer in hamster models,
and taurocholic acid and DCA have been im-
plicated in diisopropanolnitrosamine-induced
biliary tract cancer.
21,22 Also, the role of secondary
bile acids, such as DCA and LCA, together with
environmental and genetic factors, is well
recognized in colon cancer.
23,24 These indirect
association, however, cause difficulty in proving a
bile acid induced carcinogenic process.
Even though there are not many studies that
actually measured bile acid in patients with
biliary neoplasm, contrary to our study some
reported increased secondary bile acid. The
difference in methods might contribute to this
discrepancy. First, Strom et al believed that there
might be the difference of accuracy between old
methods and high pressure liquid chromato-
graphy, which also measured bile acid in our
study.
10 There is also a concentration problem.
Many factors could affect the concentration of bile
acid. Just comparing the concentration of
secondary bile acid between malignant and
benign diseases might be not reliable. We rather
compared the proportions of each bile acid.
Finally, there is a matter of control group. Lee et
al reported increased secondary bile acid in bileJeong Youp Park, et al.
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juice of patients with bile duct cancer.
11 However,
in that study patients with choledocholithiasis
were control group. We did not think patients
with biliary stone were good candidates for
control group.
There was no significant difference of UDCA
between cancer and benign disease observed. A
previously reported proportion of UDCA in
gallbladder disease was much higher than in our
results.
10 Association between cancer and UDCA
seemed to contradict other studies.
2-6 However,
there is a study that demonstrated ursodeoxycho-
late further increased bile-duct cell proliferative
response induced by partial bile-duct ligation in
rats.
25 More studies are needed to find a role of
UDCA in carcinogenesis.
Although our study attempted to collect
samples under controlled conditions, differences
of liver function among groups could not be
avoided due to rarity of biliary neoplasm.
10
Whether the differences affected the concentration
and proportion of bile acids is unknown. White
blood cell count in cancer and stone group had
rather large standard deviation because it was not
always possible to collect bile juice after inflam-
mation subsided completely. Also, control group
was significantly younger than disease groups.
Collection methods were varied among subjects,
and bile collected by gallbladder puncture could
be more concentrated than other methods. In
addition, conditions such as non-functioning
gallbladder, sphincteroplasty, fasting, etc could
also affect the concentration of bile acid.
26,27 Even
though there were such limitations in this study,
results were comparable to previous findings,
which also showed that total bile concentration
and DCA proportion were significantly lower in
the cancer group.
10 Even though it was not sig-
nificant, comparison in non-obstructive diseases
showed tendency for decreased total bile acid and
DCA in the cancer group compared to stone
group, and there was no difference of liver
function test, except alkaline phosphatase.
In conclusion, in this study, total bile acid
concentrations and compositions were measured
and compared among subjects with biliary cancer,
biliary stone pathology, and controls. Total bile
concentration and DCA proportion were lower in
the cancer group. Bile duct obstruction contri-
buted but did not completely account for the
differences in total bile concentration and com-
position. We suspect the alteration of bile acid
transport might decrease bile acid excretion and
cause the accumulation of carcinogenic bile acid in
bile duct epithelium. Further studies are needed
to prove association between bile acid composi-
tion and carcinogenesis.
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